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Introduction
Patients with ischemic stroke (IS) or transient ischemic attack (TIA) are at high risk of recurrent stroke and a considerable proportion of these recurrent events occur during the first a few days after the index stroke or TIA. [1] [2] [3] [4] Antiplatelet therapy reduces the risk of vascular events in high risk patients by around 22% on average, as shown by a meta-analysis of 195 trials with different treatment durations. 5 Therefore, current guidelines recommend antiplatelet therapy, including aspirin, clopidogrel, or aspirin plus dipyridamole, for prevention of stroke recurrence and other vascular events in these patients. [6] [7] [8] For example, the 2008 National Institute for Health and Clinical Excellence (NICE) guideline recommends the use of aspirin alone for the treatment of acute IS and TIA. 8 Aspirin plus dipyridamole is the only dual antiplatelet therapy recommended by current guidelines. 6, 7 In the coronary circulation, the use of dual or triple antiplatelet agents is the standard practice for acute coronary syndrome (ACS). 9 However, dual antiplatelet therapies, expect for the combination of aspirin and dipyridamole, have not been established in treatment of acute non-cardioembolic IS and TIA. Large randomized controlled trials (RCTs) have failed to show the efficacy and safety of dual versus mono antiplatelet therapies in long-term secondary stroke prevention. [10] [11] [12] [13] However, these large trials involved many different study populations, and treatment was often started after the initial high risk phase and was given for several years, increasing the risk of potential side effects, particularly bleeding. Uncertainties remain concerning the efficacy and safety of dual therapy for IS or TIA in the acute phase; the higher recurrent stroke risk during this period might merit a more intensive antiplatelet regimen. This hypothesis was supported by surrogate markers RCT [the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial 14 and the Clopidogrel plus Aspirin acute IS and TIA. 8 Aspirin plus dipyridamole is the only dual antiplatelet therap py y y re e eco comm mm mmen en end de ded by current guidelines. 6, 7 for Infarction Reduction in Acute Stroke or Transient Ischemic Attack Patients with Large Artery Stenosis and Microembolic Signals (CLAIR) trial 15 ], which showed that dual antiplatelet therapy was more effective at reducing cerebral embolization than monotherapy.
A previous meta-analysis synthesizing only acute data (patients randomized antiplatelet therapy versus mono therapy. The risk of major bleeding tended to be increased with dual therapy, although this was not statistically significant (RR 2.09, 95%CI 0.86-5.06, P=0.10). 16 Benefit was only seen across all trials and not for any particular comparison of dual versus mono antiplatelet therapy. However, this added evidence favoring the use of dual antiplatelet therapy in treatment of acute IS or TIA.
The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial 17, 18 (Clinicaltrials.gov identifier NCT00979589) is a randomized, double-blind, multicenter, placebo-controlled trial designed to test efficacy and safety for clopidogrel plus aspirin against aspirin alone in the prevention of recurrent stroke in Chinese patients with acute minor stroke or TIA. All subjects were randomized within 24 hours of symptom onset. For the first 21 days after recruitment, patients were randomized to Group 1 with treatment of clopidogrel (300mg loading dose once then 75mg od) plus aspirin (75-300mg loading dose then 75mg od), or Group 2 with treatment of aspirin alone (75-300mg loading dose then 75mg od).
Between 21 days and 3 months, patients in Groups 1 and 2 were respectively treated with clopidogrel (75mg od) alone or aspirin (75mg od) alone. Overall, 5,170 patients were recruited (median age 62 years, and 66% males), 2584 and 2586 in the study and control groups P=0.10). 16 Benefit was only seen across all trials and not for any particular comp pa a aris is ison n n o o of f f du du dual al versus mono antiplatelet therapy. However, this added evid However, ence favoring the use of dual an nti ti ipl pl plat at at l el elet et et t t the h h ra a apy py py in treatment of acute IS or T T TI IA IA.
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multicenter, , p p pla la lace ce cebo bo bo-c -c con on ntr rol ol o le le led d tr tr tria ial l l de de esi si s gn gn gned ed ed t to o o te te test st t e eff ff fic ic icac ac acy y y an an and d d sa sa afe fe ety ty ty f f for or or c clo lo opi pi pido do dogr gr grel plus respectively, and only 0.7% of patients were lost to follow-up at 3 months. Based on an intention-to-treat analysis, the CHANCE study found that dual therapy was more effective in With the recent completion of CHANCE, we performed an updated systematic review and meta-analysis of dual versus mono antiplatelet therapy for acute non-cardioembolic IS or TIA patients within 3 days of symptom onset, to further explore the efficacy and safety of dual antiplatelet therapy initiated in the acute phase of IS and TIA. The analyses were limited to noncardioembolic IS or TIA, since effective risk reducing treatments are fundamentally different between cardioembolic and non-cardioembolic strokes.
Methods

Data Sources and Searches
We updated the previous systematic review published in Stroke in 2011, 16 with the new review including the eligible studies up to November 2012 plus CHANCE. 17, 18 The 12 eligible studies up to April 2011 in the previous meta-analysis 16 were also included in this current meta-analysis.
For other potentially eligible studies published after 2011, we searched PubMed for relevant articles from January 2011 to November 2012, with search words of "antiplatelet therapy", "aspirin", "dipyridamole", "clopidogrel", "ticlopidine" ,"prasugrel", "cilostazol", "triflusal", "glycoprotein IIb/IIIa receptor antagonists", "stroke", "cerebral ischemia", "cerebral infarction", "transient ischemic attack" and "randomized controlled trial", and we also performed manual search of references from original articles and pertinent reviews. Searches were restricted to completed trials in human beings with abstracts or full-texts published in English. The search between cardioembolic and non-cardioembolic strokes.
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Data Extraction and Quality Assessment
For the present meta-analysis, we independently repeated data extraction from the 12 studies included in the previous systematic review 16 and cross checked our results with those published previously 16 . However, unpublished subgroup data from these 12 studies were used directly from the previous systematic review 16 in the present meta-analysis. Further, for studies published from April 2011 to November 2012, study quality was independently assessed and data were deficit attributed to focal brain ischemia las ting less or more than 24 hours, respe e ect ctiv iv ive el ely. y. wi wi ith th th w w wha hat t we we were re u u use se ed d i in n t t the he p pri r r ma ma mary ry ry s stu tu udi di ies es es, , , wh wh whic ich h h we we were re s s sim im imil il lar ar a b b bet et etwe we w e en en t the he e C C CHA HA HAN N NCE E E tr tr ria ial l an n nd d he other prim m mar ar ary y y st st stud ud udie ie ies. s C C Car ar ardi i ioe oe oemb mb mbol ol lic ic i s s str tr trok ok oke e e wa wa was s s de defi fi fine ne ned d d in in n m m mos os st t t of of of t t the he he p pri ri ima ma mary ry ry s s stu t dies as independently extracted by two authors (X.L. and W.L.) using a standardized form with the help and supervision from other authors (K.S.L.W., C.M. and J.T.). Disagreements were resolved by consensus. Besides, data from CHANCE were provided by the principal investigator of the trial.
The following data were extracted: Publication characteristics, countries or regions of the study, study centers (single or multicenter), blinding, patient characteristics, sample size of patients enrolled and randomized within 3 days of ictus, treatment groups (medications and dosages), onset-to-treatment interval, treatment duration for dual therapy and overall treatment duration, duration of follow-up, completeness of follow-up, and efficacy and safety outcomes.
The efficacy outcomes evaluated were stroke recurrence and the composite of stroke, TIA, ACS and all death. The safety outcome was major bleeding. All the three efficacy and safety outcomes were defined in accordance with what were used in the primary studies included. ACS in the present meta-analysis was defined as including the outcomes of myocardial infarction and unstable angina pectoris in the primary studies. Major bleeding in the primary studies were mostly defined in accordance with moderate-to-severe bleeding by the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition.
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Data Synthesis and Analysis
All data were analyzed using Cochrane Review Manager (version 5.2). Primary analyses were performed for each outcome, with trials subdivided by the different medications assessed. The overall estimates from all previous trials were compared with the CHANCE study, and with the updated overall results across all trials included in the current meta-analysis. For each outcome,
we performed a sensitivity analysis by restricting the analysis to double-blind studies, to test if the results of the present meta-analysis were sensitive to certain restrictions on the data included.
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For all outcomes, RR and 95% CIs were calculated using the DerSimonian and Laird randomeffects model. 20 Between-study and between-subgroup heterogeneities, which were variations in treatment effects of dual versus mono antiplatelet therapies across studies or subgroups regarding the three efficacy and safety outcomes, were evaluated by calculating the I 2 statistic and the Cochrane Q ( 2 ) statistic. Publication bias of studies with different sample sizes was assessed by performing funnel plots. 21 Two-sided p-values of <0.05 were considered statistically significant, except for the heterogeneity test in which p-values of <0.10 were used.
Results
Study selection and characteristics
All the 12 studies 10-12, 14, 15, 22-28 in the previous meta-analysis 16 were included. For other updated relevant studies from January 2011 to November 2012 (as shown in the flow chart for study selection in the Supplemental Figure 1) , an electronic search of PubMed and manual search of references from original articles and pertinent reviews identified 219 publications. By reviewing title and abstract, 209 articles were excluded. Ten articles were reviewed by full-text for details, and 9 of them were excluded: not a RCT (n=2), no acute data present (n=1), duplicate publications (n=2), or other reasons (n=4). Therefore, besides CHANCE, only one other eligible RCT published after January 2011 was identified, which compared cilostazol (100mg bd) plus aspirin (300mg loading dose then 100mg od) versus aspirin alone (300mg loading dose then 100mg od) in 76 adult patients (mean age 67 years, and 74% males) with acute noncardioembolic IS, though whether treatment was blinded is unknown. 29 Therefore in total, there were 14 studies with 9,012 patients in the present systematic review and meta-analysis (study characteristics are listed in Table 1 ), among which 7 were
All the 12 studies 10-12, 14, 15, 22-28 in the previous meta-analysis 16 were included. . Te Te T n n n ar ar arti ti t cl les es es w w wer er ere e e re re r vi vi iew ew ewed ed ed b b by y y fu fu ull ll l-t -t tex ex ext t t fo f r details, double-blind, 9 were intention-to-treat, and 11 had concealed allocation. 
Synthesis of results
For analyses of efficacy and safety outcomes, no evidence existed for between-study or between- The results were consistent between CHANCE and all other trials; as with the outcome of stroke recurrence, the 95% CI of the overall effect for the composite efficacy outcome became much narrower after adding data from CHANCE (Figure 4) .
Ten studies had data regarding the safety outcome of major bleeding, which were analyzed in the current meta-analysis for this outcome. It occurred in about 0.5% and 0.4% of patients in the dual and monotherapy groups, respectively, when all trial data were combined. As compared with mono antiplatelet therapy, dual therapy for acute IS or TIA patients was not associated with a significant increase in the risk of major bleeding (RR 1.35, 95%CI 0.70-2.59, P=0.37; Figure 5 and Figure 6 ).
Sensitivity analyses restricted to the 7 double-blind trials 10-12, 14, 17, 24, 27 showed similar results for each outcome ( Table 2 ) when compared with the full analyses.
In the subgroup of the 5 RCTs comparing clopidogrel plus aspirin versus aspirin alone, 4 trials 14, 15, 17, 27 had dual therapy of 3 months (7 days to 3 months), while the other one 11 Te Ten n n st st stud udi i ies s s ha ha ad d da da d ta ta r r reg eg egar ar ard d din in ing g th th he e e sa sa safe fe ety ty t o o ou ut utco o ome me me o o of ma ma m j jo jor r r bl bl b e e eed di ding ng g, , , wh wh w ic ic ch h h we we ere e e analyzed in th th he e e cu cu urr rr rren en ent t t me me m ta ta ta-a -a ana na naly ly ysi si sis s fo fo for r th th this is i ou ou outc tc tcom om ome. e I I It t t oc oc occu cu curr rr rred e e i i in n n ab ab abou ou out t t 0. 0.5% 5% 5% a a and nd nd 0.4% of median treatment duration of 28 months for dual therapy ( Table 1) 
Discussion
In this systematic review and meta-analysis, we included 14 RCTs (9,012 patients) comparing dual versus mono antiplatelet therapy for acute non-cardioembolic IS or TIA within 3 days of ictus. We found that when compared with mono antiplatelet therapy, dual therapy was associated with a reduction in stroke recurrence, and composite vascular events, but without a significant increase in the risk of major bleeding. A sensitivity analysis restricted to the 7 double-blind RCTs showed similar results, which indicated that results of the present meta-analysis were or the composite efficacy outcome, as compared with monotherapies ( Figures 1 1 an an and d 3 3 3) , ), ), t t tho ho houg ug u h here were no significant between-subgroup heterogeneities throughout the analyses. For trials For trials co omp mp mpar ar ari in ing g g as aspi p ri ri in n n p plus dipyridamole versus asp pi i iri ri r n n alone, there w w wer e e no no no s significant differences b be etw w ween dual a ant nt tip p pla ate te ele e et t t th th the er era ap apy y an an and d mo monoth th t e erap p py y in t th he he e eff f fic icac ac cy y o out utc co come me me o of f f st stro ro roke ke ke r rec ec cu ur urre re en nc nce In subgroup analyses of clopidogrel plus aspirin versus aspirin alone in the current metaanalysis, significant reductions were found in risks of stroke recurrence and the composite of vascular events and all death (Figures 1 and 3) . This was different from results of the previous meta-analysis, in which the effects of clopidogrel plus aspirin versus aspirin alone on both of the two efficacy outcomes were not statistically significant. 16 But results on the safety outcome of major bleeding in this subgroup were similar between the current review and the previous one, 16 both of which indicated a non-significant increase in major bleeding with dual versus monotherapy. Therefore, the CHANCE study added evidence for the superiority of clopidogrel plus aspirin over aspirin alone for the prevention of stroke recurrence and other vascular events in acute IS or TIA patients, but meanwhile did not alter the non-significant increase of major bleeding in patients treated with the dual therapy. Other subgroup analyses showed no significant reduction in stroke recurrence and the composite efficacy outcome in patients treated with dual therapy, which were consistent with the previous meta-analysis. 16 Specifically, aspirin plus dipyridamole was found to be not significantly different from aspirin alone on the efficacy and safety outcomes in the present meta-analysis. However, this did not challenge recommendations of aspirin plus dipyridamole for management of IS and TIA in current guidelines, 6, 7 due to the reason that only patients recruited and randomized within 3 days of ictus, which was a small portion of subjects recruited in the RCTs assessing treatment effects of aspirin plus dipyridamole wo efficacy outcomes were not statistically significant. 16 But results on the safe et ty ty o o out ut tco c come me me o of f major bleeding in this subgroup were similar between the current review and the previous one, 16 bo oth th h o o of f f wh wh whic ic ich h h in ndi di dica cated a non-significant increa ase se se i in n major bleedi di ing n w w wit it ith h h dual versus m mon no notherapy. T The he h re refo fo fore e e, th th the e e CH C CHAN AN ANC CE E s stud dy dy add POINT study is very similar to the CHANCE study and will be included in an updated metaanalysis when finished in future. In contrast the TARDIS study compares triple antiplatelet agents with current guideline-based therapy which may include dual antiplatelet agents and thus will not be covered in an updated meta-analysis like this one.
There are several limitations of the present systematic review and meta-analysis. First, included studies varied in relation to the study population, stroke severity, antiplatelet medications, onset-to-treatment interval, treatment and follow-up durations, and other aspects.
All of these factors could be potential confounders. Secondly, for some of the studies included, IS or TIA patients within 3 days of symptom onset were not the primary target population and were usually a small portion of the primary study populations. Confounders might not be well balanced between dual and monotherapy groups for such patients. Thirdly, CHANCE, as a large trial, accounted for around 50% of participants in the meta-analysis, and therefore its results drove much of the findings. Beside, CHANCE investigated dual versus monotherapy and then different monotherapies in acute IS and TIA, the study design of which was different in this point as compared with most of other RCTs included in the present meta-analysis. We cannot determine the extent to which clopidogrel alone from day 21 to the end of the 3rd month post ictus (following 21 days of dual clopidogrel and aspirin therapy) in the CHANCE Trial drove the difference in recurrent event rates compared to 3 months of aspirin monotherapy.
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